SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-010682
Filing Date
2020-08-14
Accepted
2020-08-14 16:48:08
Documents
80
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20200630x10q.htm 10-Q 1505726
2 EX-10.6 otlk-20200630ex106b7f081.htm EX-10.6 91331
3 EX-31.1 otlk-20200630ex311516b5f.htm EX-31.1 9535
4 EX-32.1 otlk-20200630ex321dd1d48.htm EX-32.1 6304
  Complete submission text file 0001558370-20-010682.txt   7870049

Data Files

Seq Description Document Type Size
5 EX-101.INS otlk-20200630.xml EX-101.INS 1788076
6 EX-101.SCH otlk-20200630.xsd EX-101.SCH 59148
7 EX-101.CAL otlk-20200630_cal.xml EX-101.CAL 62303
8 EX-101.DEF otlk-20200630_def.xml EX-101.DEF 259520
9 EX-101.LAB otlk-20200630_lab.xml EX-101.LAB 485231
10 EX-101.PRE otlk-20200630_pre.xml EX-101.PRE 461496
Mailing Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852
Business Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 201106125
SIC: 2836 Biological Products, (No Diagnostic Substances)